Literature DB >> 16134735

Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET).

M F Kraus1, G S Smith, M Butters, A J Donnell, E Dixon, C Yilong, D Marion.   

Abstract

PRIMARY
OBJECTIVE: This study was performed to assess effects of amantadine (AMH), a dopaminergic agent and NMDA antagonist, on chronic traumatic brain injury (TBI). The primary hypotheses were that amantadine treatment would result in executive function improvement and increased activity in pre-frontal cortex. RESEARCH
DESIGN: An open-label design was used.
METHODS: Twenty-two subjects underwent neuropsychological testing pre- and post-12 week treatment. Six subjects also underwent PET scanning. INTERVENTION: Amantadine 400 mg was administered per day.
RESULTS: Significant improvements on tests of executive function were observed with treatment. Analysis of PET data demonstrated a significant increase in left pre-frontal cortex glucose metabolism. There was a significant positive correlation between executive domain scores and left pre-frontal glucose metabolism.
CONCLUSIONS: This is the first known study to assess amantadine in chronic TBI using PET and the data are consistent with the hypotheses. The conduction of further studies is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134735     DOI: 10.1080/02699050400025059

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  29 in total

1.  Targeting Dopamine in Acute Traumatic Brain Injury.

Authors:  James W Bales; Anthony E Kline; Amy K Wagner; C Edward Dixon
Journal:  Open Drug Discov J       Date:  2010

Review 2.  Medical therapies for concussion.

Authors:  William P Meehan
Journal:  Clin Sports Med       Date:  2011-01       Impact factor: 2.182

Review 3.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

Review 4.  What is the role of brain mechanisms underlying arousal in recovery of motor function after structural brain injuries?

Authors:  Andrew M Goldfine; Nicholas D Schiff
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

Review 5.  Neurotransmitter changes after traumatic brain injury: an update for new treatment strategies.

Authors:  Jennifer L McGuire; Laura B Ngwenya; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

6.  Treatment of Apathy in Huntington's Disease and Other Movement Disorders.

Authors:  Ashok Krishnamoorthy; David Craufurd
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

7.  The dopamine and cAMP regulated phosphoprotein, 32 kDa (DARPP-32) signaling pathway: a novel therapeutic target in traumatic brain injury.

Authors:  James W Bales; Hong Q Yan; Xiecheng Ma; Youming Li; Ranmal Samarasinghe; C Edward Dixon
Journal:  Exp Neurol       Date:  2011-03-01       Impact factor: 5.330

Review 8.  Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.

Authors:  Alexandra N Garcia; Mansi A Shah; C Edward Dixon; Amy K Wagner; Anthony E Kline
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

9.  Cocaine self-administration is increased after frontal traumatic brain injury and associated with neuroinflammation.

Authors:  Cole Vonder Haar; Jacqueline-Marie N Ferland; Sukhbir Kaur; Lara-Kirstie Riparip; Susanna Rosi; Catharine A Winstanley
Journal:  Eur J Neurosci       Date:  2018-10-10       Impact factor: 3.386

10.  Cognitive function in the locked-in syndrome.

Authors:  Caroline Schnakers; Steve Majerus; Serge Goldman; Melanie Boly; Philippe Van Eeckhout; Stephane Gay; Frederic Pellas; Valerie Bartsch; Philippe Peigneux; Gustave Moonen; Steven Laureys
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.